By Fineline Cube Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced positive top-line results from a Phase III clinical study evaluating LAE002 (afuresertib) combined with fulvestrant in patients with PIK3CA/AKT1/PTEN-altered HR+/HER2- locally advanced or metastatic breast cancer (LA/mBC) who progressed on prior endocrine therapy with or without CDK4/6 inhibitors.
Clinical Trial Results – Phase III Study
| Endpoint | LAE002 + Fulvestrant | Placebo + Fulvestrant | Hazard Ratio (HR) |
|---|---|---|---|
| Median Progression-Free Survival (PFS) | 7.6 months | 2.0 months | 0.33 |
| Statistical Significance | p < 0.0001 | — | Highly significant |
The study met its primary endpoint with unprecedented efficacy, demonstrating a 74% reduction in risk of disease progression or death compared to the control arm.
Drug Profile & Mechanism of Action
- Compound: LAE002 (afuresertib) – once-daily oral AKT inhibitor
- Target: Potent inhibition of all three AKT isoforms (AKT1, AKT2, and AKT3)
- Development Stage: One of only two AKT inhibitors globally in late-stage clinical development for breast and prostate cancer
- Safety Profile: Well tolerated with very low treatment discontinuation rates due to adverse events; consistent with previously reported combination data
Strategic Partnership & Commercial Rights
In November 2025, Qilu Pharmaceutical secured development and commercialization rights for LAE002 in Greater China through a landmark USD 2 billion licensing agreement with Laekna, highlighting the asset’s significant commercial potential in the world’s second-largest pharmaceutical market.
Market Opportunity Analysis
- Target Population: HR+/HER2- breast cancer patients with PIK3CA/AKT1/PTEN alterations represent a substantial subset of the metastatic breast cancer population
- Unmet Need: Limited effective options exist for patients progressing after CDK4/6 inhibitor therapy
- Competitive Landscape: LAE002’s pan-AKT inhibition profile differentiates it from selective AKT inhibitors in development
- Commercial Potential: The dramatic PFS improvement (7.6 vs 2.0 months) positions LAE002 as a potential new standard of care in this difficult-to-treat population
Strategic Implications
- Regulatory Pathway: Strong Phase III data supports expedited regulatory submissions in multiple jurisdictions
- Global Expansion: Success validates Laekna’s international development strategy for innovative oncology assets
- Pipeline Validation: Demonstrates the company’s capability to advance complex targeted therapies through late-stage development
- Partnership Value: Qilu’s USD 2 billion investment reflects confidence in LAE002’s commercial prospects in Greater China
Industry Outlook
The AKT pathway represents a critical therapeutic target in hormone receptor-positive breast cancer, particularly in tumors with PI3K/AKT/PTEN pathway alterations. LAE002’s ability to inhibit all three AKT isoforms may provide superior efficacy compared to isoform-selective inhibitors, addressing a key mechanism of resistance in this patient population.
If approved, LAE002 would fill a significant gap in the treatment paradigm for HR+/HER2- metastatic breast cancer, offering hope to patients who have exhausted current standard therapies including CDK4/6 inhibitors.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial opportunities for LAE002. Actual results may differ due to risks including regulatory decisions, competitive dynamics, manufacturing challenges, and market acceptance of novel AKT inhibitors in breast cancer treatment.-Fineline Info & Tech